抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性中地图样萎缩发生率:根据观察-计划方案对雷珠单抗或阿柏西普个体化治疗需求的风险因素评估
研究纳入149只基线无地图样萎缩(MA)的新生血管性年龄相关性黄斑变性眼,分别接受雷珠单抗或阿柏西普的观察-计划可变剂量方案治疗,2年时63只眼(42%)出现新发MA。多因素分析显示MA独立风险因素包括较少的抗VEGF注射次数(P=0.011)、色素脱失(P=0.0004)、网状假性玻璃膜疣(P=0.0005)、较低基线视力(P=0.0006)和视网膜血管瘤样增生(P=0.001);药物类型与MA发生率无显著关联(P=0.21)。
要点
- 观察-计划可变剂量方案下,2年新发MA发生率为42%(63/149眼)。
- 所需注射次数越少,MA发生率越高(P=0.011)。
- 色素脱失、网状假性玻璃膜疣、较低基线视力、视网膜血管瘤样增生为独立风险因素。
主要发现
- 149只眼/患者(平均年龄79.0岁)中63只眼(42%)出现新发MA,其中阿柏西普治疗70只眼、雷珠单抗治疗79只眼。
- 单变量分析显示MA与多个基线因素相关,多变量逐步逻辑回归确认以下为独立风险因素:较少的抗VEGF注射次数(P=0.011)、色素脱失(P=0.0004)、网状假性玻璃膜疣(P=0.0005)、较低基线视力(P=0.0006)、视网膜血管瘤样增生(P=0.001)。
- 药物类型与MA发生率无显著关联(P=0.21)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate factors associated with macular atrophy (MA) incidence in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept in an Observe-and-Plan variable dosing regimen. METHODS: Information was obtained from two identical prospective treatment protocols using ranibizumab or aflibercept in a variable dosing regimen termed "Observe and Plan." Eyes without MA at baseline were included. New atrophy at the final 2-year visit was investigated with univariate and multivariate analysis to identify associated risk factors, focusing on treatment factors. RESULTS: De novo MA developed in 63 (42%) of 149 eyes/patients (mean age 79.0 years), in 70 eyes treated using aflibercept and 79 eyes using ranibizumab. The univariate analysis showed multiple associations of MA with baseline factors, of which the following were confirmed as independent risk factors after multivariate stepwise logistic regression: lower number of anti-vascular endothelial growth factors injections (P = 0.011), depigmentation (P = 0.0004), reticular pseudodrusen (P = 0.0005), lower baseline visual acuity (P = 0.0006), and retinal angiomatous proliferation (P = 0.001). The drug type showed no significant association with MA incidence (P = 0.21). CONCLUSION: Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA.
引用
- Mantel I, Dirani A, Zola M, et al. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Retina. 2019. PMID: 29370035. doi:10.1097/IAE.0000000000002054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。